Latest news and press releases about iSpecimen Inc. (ISPC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, bioba...
Price
| Price | $1.37 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.10 |
| EV / EBITDA | 0.39 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -524.37% |
| Return on Invested Capital | -476.39% |
| Return on Assets | -154.47% |
| Gross Margin | -151.47% |
| Operating Margin | -2020.04% |
| Net Margin | -2449.04% |
Related companies: BIAF · BIVI · BJDX · GLMD · HSCS · NDRA · SHPH
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of ISPC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks